Adgero Biopharmaceuticals

10/26/2017

Adgero Biopharmaceuticals Appoints John Liatos as Chief Financial Officer

Click here to learn more about Adgero’s late stage development therapy for the treatment of cutaneous metastatic breast cancer (CMBC).

09/29/2017

Adgero Biopharmaceuticals Successfully Completes $3.4 Million Warrant Tender Offer

Proceeds to advance REM-001 Therapy Phase 3 clinical program in cutaneous metastatic breast cancer

https://goo.gl/8mzhE8

Download as PDF September 29, 2017 Proceeds to advance REM-001 Therapy Phase 3 clinical program in cutaneous metastatic breast cancer PRINCETON, NJ -- (Marketwired) -- 09/29/17 -- Adgero Biopharmaceuticals Holdings, Inc. ("Adgero" or the "Company"), a privately-held biopharmaceutical company leverag...

09/14/2017

Adgero Biopharmaceuticals Appoints Felix T. Garzon, M.D., Ph.D. as Chief Medical Officer to lead its clinical development efforts with an initial focus on its lead product for Cutaneous Metastatic Breast Cancer (CMBC)

Proven international track record with successful development and approval of new oncology drugs including Halaven (Eribulin) for breast cancer

Extensive experience in strategic planning and implementation of development for late stage drugs

https://goo.gl/URCmPk

Download as PDF September 14, 2017 PRINCETON, NJ -- (Marketwired) -- 09/14/17 -- Proven international track record with successful development and approval of new oncology drugs including Halaven (Eribulin) for breast cancer Extensive experience in strategic planning and implementation of developmen...

04/10/2017

Positive Clinical Data of Adgero Biopharmaceuticals' REM-001 Therapy for the Treatment of Cutaneous Metastatic Breast Cancer Presented at 37th ASLMS Annual Conference

https://goo.gl/zi4m8m

("Adgero" or the "Company"), a privately-held biopharmaceutical company leveraging its late stage photodynamic therapy ("PDT") platform for the treatment of serious cutaneous oncology indications, announced today that positive data from the clinical studies of the Company's lead product candidate,

02/14/2017

Adgero Expands Executive Management Team with Appointment of Jane M. Maida as Chief Financial Officer.

https://goo.gl/TB3deY

("Adgero" or the "Company"), a privately-held biopharmaceutical company leveraging its late stage photodynamic therapy ("PDT") platform for the treatment of serious oncology indications, announced today that it has appointed Jane M. Maida as Chief Financial Officer and Vice President of Finance.

01/26/2017

Adgero Biopharmaceuticals to Present at Noble Capital Markets' Thirteenth Annual Investor Conference

- Presentation with video webcast on Monday, January 30th at 3:00 p.m. EST -

https://goo.gl/17Ka86

01/05/2017

Adgero to Present at Biotech Showcase - Presentation with live audio webcast on Monday, January 9th at 4:00 p.m. PST

https://goo.gl/kCSBxg

Download as PDF January 05, 2017 Presentation with live audio webcast on Monday, January 9th at 4:00 p.m. PST PRINCETON, NJ -- (Marketwired) -- 01/05/17 -- Adgero Biopharmaceuticals Holdings, Inc. ("Adgero" or the "Company"), a privately-held biopharmaceutical company leveraging its late stage photo...

10/31/2016

As breast cancer awareness month comes to a close, Adgero’s CEO Frank Pikliewicz shares a message on cutaneous metastatic breast cancer and the company's dedication to the development of REM-001 as a potential treatment option.

https://goo.gl/sGN8sH

Click here to learn more about Adgero’s late stage development therapy for the treatment of cutaneous metastatic breast cancer (CMBC).

10/20/2016

Adgero Biopharmaceuticals Expands Executive Management Team with Appointment of Laura Edgerly-Pflug as Vice President of Manufacturing Operations and Quality Control

Strengthening team with extensive experience in product and process development and scale-up from bench to commercial process

https://goo.gl/ceZ5b9

Click here to learn more about Adgero’s late stage development therapy for the treatment of cutaneous metastatic breast cancer (CMBC).